Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1

Status

Unknown 182Recruiting 118Completed 101Not yet recruiting 45Active not recruiting 37Terminated 26Withdrawn 6Suspended 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 6

Conditions

Breast Neoplasms 370Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 142Colorectal Neoplasms 139Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 123Lymphoma 115Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 89Head and Neck Neoplasms 89Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 62Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

epacadostat 1durvalumab 1Valproic Acid 1Nivolumab 1Immunoglobulin G 1Disulfides 1Cisplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Nasopharyngeal Carcinoma × Clear all
NCT02289807 2021-10-15

Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy

Sun Yat-sen University

Phase NA Withdrawn
Head & Neck

Nasopharyngeal Carcinoma

NCT03390738 2021-05-03

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

The University of Hong Kong

Phase 2 Withdrawn
Head & Neck

Nasopharyngeal Carcinoma

NCT04231864 2020-10-26

Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

University of California, San Francisco

Phase 2 Withdrawn
Head & Neck

Nasopharyngeal Carcinoma

NCT00181220 2020-05-18

Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma

Johns Hopkins University

Phase 1 Withdrawn
Head & Neck

Nasopharyngeal Carcinoma

NCT00367718 2020-05-18

Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

Johns Hopkins University

Phase 2 Withdrawn
Head & Neck

Nasopharyngeal Carcinoma

NCT00515957 2012-04-16

DELLA

Baylor College of Medicine

Phase 1 Withdrawn
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡